JP2006517089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517089A5 JP2006517089A5 JP2004538776A JP2004538776A JP2006517089A5 JP 2006517089 A5 JP2006517089 A5 JP 2006517089A5 JP 2004538776 A JP2004538776 A JP 2004538776A JP 2004538776 A JP2004538776 A JP 2004538776A JP 2006517089 A5 JP2006517089 A5 JP 2006517089A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- group
- amino acid
- substitution
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108010054265 Factor VIIa Proteins 0.000 claims 3
- 102200102393 c.194T>A Human genes 0.000 claims 3
- 229940012414 factor viia Drugs 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229940099816 human factor vii Drugs 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102200118254 rs33995148 Human genes 0.000 claims 2
- 102220635301 Adenylate kinase isoenzyme 6_I42R_mutation Human genes 0.000 claims 1
- 102220471770 Fructose-bisphosphate aldolase A_E82Q_mutation Human genes 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 102220547369 Protein APCDD1_L65S_mutation Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220297938 rs375722926 Human genes 0.000 claims 1
- 102220024669 rs59270054 Human genes 0.000 claims 1
- 102220164564 rs886063892 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41483602P | 2002-09-30 | 2002-09-30 | |
| US47964203P | 2003-06-19 | 2003-06-19 | |
| PCT/DK2003/000632 WO2004029091A2 (en) | 2002-09-30 | 2003-09-26 | FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517089A JP2006517089A (ja) | 2006-07-20 |
| JP2006517089A5 true JP2006517089A5 (https=) | 2006-11-16 |
| JP4472526B2 JP4472526B2 (ja) | 2010-06-02 |
Family
ID=32045297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004538776A Expired - Fee Related JP4472526B2 (ja) | 2002-09-30 | 2003-09-26 | 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060166874A1 (https=) |
| EP (1) | EP1549677B1 (https=) |
| JP (1) | JP4472526B2 (https=) |
| AT (1) | ATE505487T1 (https=) |
| AU (2) | AU2003266931B2 (https=) |
| CA (2) | CA2840692A1 (https=) |
| DE (1) | DE60336741D1 (https=) |
| DK (1) | DK1549677T3 (https=) |
| WO (1) | WO2004029091A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| SI1499719T1 (sl) * | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
| DK1608745T3 (da) * | 2003-03-20 | 2009-06-15 | Bayer Healthcare Llc | FVII eller FVIIa-Varianter |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| NZ573412A (en) | 2003-06-19 | 2010-09-30 | Maxygen Holdings Ltd | Factor VII or VIIa Gla domain variants |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| ES2381110T3 (es) | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| EP1711513B1 (en) | 2003-12-01 | 2014-07-02 | Novo Nordisk Health Care AG | Nanofiltration of factor vii solutions to remove virus |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| RU2373953C2 (ru) | 2003-12-19 | 2009-11-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированная композиция, содержащая полипептид фактора vii |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| ATE469216T1 (de) | 2004-08-17 | 2010-06-15 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
| US20080108557A1 (en) * | 2004-09-29 | 2008-05-08 | Novo Nordisk Healthcare A/G | Modified Proteins |
| US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| ES2395544T3 (es) | 2004-12-23 | 2013-02-13 | Novo Nordisk Health Care Ag | Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| ES2397851T3 (es) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
| JP5690047B2 (ja) * | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| ES2516694T3 (es) | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
| WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| WO2008078189A2 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| EP1972687A1 (en) * | 2007-03-23 | 2008-09-24 | GenOdyssee | Polynucleotides and polypeptides of human factor VII gene, SNPs |
| KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법 |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| KR101582841B1 (ko) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | 콘쥬게이트된 인자 ｖｉｉｉ 분자 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| US12570955B2 (en) | 2019-11-22 | 2026-03-10 | Sigilon Therapeutics, Inc. | Monoclonal cell lines expressing an exogenous substance and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| AU703110B2 (en) * | 1993-05-21 | 1999-03-18 | Novo Nordisk A/S | Modified factor VII |
| EP0946715B1 (en) * | 1996-11-08 | 2006-03-29 | Oklahoma Medical Research Foundation | Use of a modified protein c |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| MXPA03001984A (es) * | 2000-09-13 | 2003-08-29 | Novo Nordisk Healthcare Ag | Variantes de factor vii de coagulacion humano. |
| EP1325127B1 (en) * | 2000-10-02 | 2009-03-11 | Novo Nordisk Health Care AG | Method for the production of vitamin k-dependent proteins |
| AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| SI1499719T1 (sl) * | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
-
2003
- 2003-09-26 AU AU2003266931A patent/AU2003266931B2/en not_active Ceased
- 2003-09-26 DE DE60336741T patent/DE60336741D1/de not_active Expired - Lifetime
- 2003-09-26 AT AT03747838T patent/ATE505487T1/de not_active IP Right Cessation
- 2003-09-26 DK DK03747838.5T patent/DK1549677T3/da active
- 2003-09-26 US US10/529,624 patent/US20060166874A1/en not_active Abandoned
- 2003-09-26 JP JP2004538776A patent/JP4472526B2/ja not_active Expired - Fee Related
- 2003-09-26 WO PCT/DK2003/000632 patent/WO2004029091A2/en not_active Ceased
- 2003-09-26 CA CA2840692A patent/CA2840692A1/en not_active Abandoned
- 2003-09-26 EP EP03747838A patent/EP1549677B1/en not_active Expired - Lifetime
- 2003-09-26 CA CA2502162A patent/CA2502162C/en not_active Expired - Fee Related
-
2010
- 2010-03-30 AU AU2010201266A patent/AU2010201266A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517089A5 (https=) | ||
| JP2006521098A5 (https=) | ||
| JP2012105650A5 (https=) | ||
| CA2519873A1 (en) | Fvii or fviia variants | |
| KR101623602B1 (ko) | 변형된 제ⅶ 인자 폴리펩티드 및 그의 용도 | |
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2008538183A5 (https=) | ||
| JP2012518420A5 (https=) | ||
| RU2006101391A (ru) | ВАРИАНТЫ ДОМЕНА GLa ФАКТОРА VII ИЛИ VIIa | |
| PT2147096E (pt) | Polipéptidos do factor vii modificados e suas utilizações | |
| ES3010346T3 (en) | Long-acting coagulation factors and uses thereof | |
| JP2013502458A5 (https=) | ||
| ATE437221T1 (de) | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie | |
| JP2002528060A5 (https=) | ||
| DK1549677T3 (da) | FVII- eller FVIIa-varianter med forøget koagulationsaktivitet | |
| RU2012102339A (ru) | Полипептиды из neisseria meningitidis | |
| ATE434447T1 (de) | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion | |
| JP2011518179A5 (https=) | ||
| JP2003525906A5 (https=) | ||
| JP2018508530A5 (https=) | ||
| KR20220166363A (ko) | 장기-작용성 응고 인자 및 그의 제조 방법 | |
| ATE435657T1 (de) | Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung | |
| JP2022517267A (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| JP2004531242A5 (https=) | ||
| MXPA05003818A (es) | Perfilamiento de la expresion genica de muestras ffpe. |